New drug combo could help breast cancer patients who Don't respond to standard therapy
NCT ID NCT07528898
First seen Apr 17, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This study tests a personalized approach for people with HER2-positive breast cancer. About 100 participants will start with standard treatment. If their tumor shrinks less than 40% after two cycles, they will switch to a new drug combination (SHR-A1811 plus pertuzumab) to try to improve outcomes. The goal is to see if this switch leads to a complete disappearance of cancer at surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.